No­var­tis touts more late-stage da­ta for in­clisir­an, the once-cen­ter­piece heart drug spurned by the FDA

No­var­tis bet large on The Med­i­cines Com­pa­ny’s RNAi heart drug in­clisir­an, ex­pect­ing to shake up that seg­ment of the mar­ket with a swift US ap­proval. But af­ter get­ting stiff-armed by the FDA last year, the phar­ma gi­ant’s now re­leas­ing more post-hoc da­ta in the hopes of fi­nal­ly run­ning it past the goal line.

Pa­tients who took in­clisir­an — or Leqvio, as it’s mar­ket­ed in the EU — in three Phase III tri­als saw sus­tained re­duc­tions in bad cho­les­terol of about 50% com­pared to place­bo at month 17, re­gard­less of body mass in­dex, No­var­tis an­nounced at this year’s Amer­i­can Heart As­so­ci­a­tion vir­tu­al con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER